

Press Release  
Gothenburg, September 24, 2018

## PEXA receives additional order from United Kingdom

**PEXA AB ("PEXA") announces the sale of a PEXA 2.0 system to University of Leicester, United Kingdom. Total sales price is Euro 35 000.**

The University of Leicester is the second university in United Kingdom to start utilising a PEXA 2.0 system in their research. The instrument is planned to be installed in October 2018.

**Dr. Salman Siddiqui, Professor of respiratory medicine and airways disease, University of Leicester:**

*- The PEXA matrix is a unique lung matrix derived from the liquid lining the surface of small airways. PEXA can be utilised to study a range of inflammatory, non-inflammatory protein and lipid/phospholipid biomarkers. As one of the largest respiratory airways disease groups in Europe we are excited to be exploring the role of PEXA in the pathogenesis of small airways disease in asthma and COPD. Our group remains excited about the prospect of evaluating the latest PEXA device for the next generation of small airways phenotyping studies in partnership with other groups.*

**Erik Ekbo, CEO at PEXA AB:**

*- That leading experts, such as Professor Siddiqui, choose to include PEXA in their research show confidence in PEXA's method, and is of course a development we are very enthusiastic about. It is particularly satisfying to note that Professor Siddiqui and his team have identified PEXA as a tool that can aid in their research on disease processes that takes place in the small airways in specific, thus contributing to the development of sensitive biomarkers as well as effective treatments for the group of asthma and COPD patients who currently are difficult to diagnose and treat.*

**For further information, please contact:**

Erik Ekbo, CEO  
Phone: +46 723-92 30 30  
E-mail: erik@pexa.se

*This information is information which PEXA AB is obligated to publish under the EU Market Abuse Regulation. The information was provided through the agency of above contact person, for publication on September 24, 2018.*

---

**PEXA AB** (556956-9246) develops and markets a research instrument with associated products and services to respiratory researchers for easy and non-invasive sampling, in order to study respiratory diseases such as asthma and chronic obstructive pulmonary disease, COPD. Sampling with PEXA can be used to detect lung diseases at an early stage. The sample can be compared to a "blood test for the small airways". The aim is to facilitate the development of reliable and more individualized diagnosis, monitoring and treatment of respiratory diseases. The original idea and research behind the method comes from the unit for Occupational and Environmental Medicine at the Sahlgrenska Academy at Gothenburg University. Commercial operations started in 2010 with the support of GU Ventures incubator, and the company is founded by inventor, key employees, business angels and GU Ventures. The company's B-shares are listed on Spotlight Stock Market.